Organization
AstraZeneca, BioPharmaceuticals Medical, Gaithersburg, MD, United States of America
1 abstract
Abstract
ANIFROLUMAB FOR PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: INTERIM ANALYSIS OF A RETROSPECTIVE COHORT STUDYOrg: University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, Leeds Teaching Hospitals NHS Trust, NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, Sorbonne University, Faculty of Medecine, Dermatology Department, Tenon Hospital INSERM U1135 (CIMI-Paris), Paris, France, Unidade de Imunologia Clínica, Centro Hospitalar e Universitário de Santo António, Vila Real de Santo António, Portugal, AstraZeneca, BioPharmaceuticals Medicine, Cambridge, United Kingdom,